Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
Sorting Out the CRISPR Patent Case
Sounds of Science Podcast
Good Assays for Bad Immunogenicity
Avoid “Bad” Immunogenicity by Using Assays That Are More Sensitive and Can Adapt to Increasingly Complex and Specialized Drugs
For full access to this article login to GEN Select now.
HTS Carving Out Hit-to-Lead Position
Researchers Are Coupling this Technology with Other Methodologies to Enable Better Screening
- Pressure to discover more hits and develop more blockbuster drugs with less time and expense spent on target screening continues to spur companies to invest in high-throughput technologies earlier in the drug discovery process. In addition, there is a trend toward combining cell biology, imaging, and in vivo experimentation skills. ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.